LY2189265 Compared to Sitagliptin in Patients With Type II Diabetes Mellitus on Metformin. Sponsored by Eli Lilly and Co.
An adaptive dose finding study and a phase III efficacy study to evaluate the effects of a once-weekly injection of LY2189625 compared to sitagliptin on glucose by measuring glycohemoglobin (HbA1c) change from baseline after 12 months in patients with type II diabetes mellitus on metformin
Enrolling. Participants must be 18 or older, with Type I diabetes mellitus for at least 12 months, current treatment with any basal bolus insulin for at least 12 months, HbA1c below or equal to 10 percent, BMI (Body Mass Index) below or equal to 35.
Zachary R. Freedman, MD, FACE
Amy Winterberger, CCRC